Physician profile
Sameer Satija
NPI 1235317876
$65,775.71
in general payments reported to CMS, 2019-2025
31 companies · $7,068 in 2025
The $7,068 reported for 2025 was more than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $5,995 · 2021: $8,568 · 2022: $8,542 · 2023: $9,204 · 2024: $8,745 · 2025: $7,068.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $23K · Travel and Lodging: $2,179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $22,839.02 |
| Travel and Lodging | $2,178.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $24,118.78 | 2019-2025 | Aveir, Ensite, Jot Dx |
| Medtronic, INC. | $18,187.97 | 2021-2025 | Cobalt Dr Mri Surescan, Azure Xt Dr Mri Surescan, Linq II |
| Pfizer INC. | $7,187.99 | 2019-2025 | |
| Boston Scientific Corporation | $3,646.66 | 2019-2025 | Watchman Flx, Watchman Access System, Watchman |
| E.R. Squibb & Sons, L.L.C. | $3,381.48 | 2019-2025 | Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $2,557.22 | 2019-2024 | Lifevest |
| Atricure, INC. | $1,407.14 | 2021-2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Biosense Webster, INC. | $1,067.16 | 2019-2025 | Carto 3, Nuvision Ice Catheter, Soundstar |
| Janssen Pharmaceuticals, INC | $728.06 | 2019-2024 | Xarelto |
| Cordis US Corp. | $641.81 | 2022-2024 | Mynx Control, Rain Sheath |
| Medtronic Vascular, INC. | $524.55 | 2019-2020 | |
| Cardiva Medical, INC. | $402.01 | 2019-2025 | Cardiva Vascade Mvp Vvcs 6-12f, Cardiva Vascade 6/7f Vcs |
| Impulse Dynamics (USA) INC. | $323.59 | 2022-2023 | Optimizer |
| Cvrx, INC. | $294.46 | 2024-2025 | Barostim Neo System |
| Sanofi-Aventis U.S. LLC | $254.90 | 2019-2024 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $166.69 | 2021 | |
| Edwards Lifesciences Corporation | $153.99 | 2024 | |
| Biotronik INC. | $138.72 | 2021 | |
| Novartis Pharmaceuticals Corporation | $118.39 | 2019 | |
| Acutus Medical, INC. | $90.20 | 2020-2023 | |
| Kiniksa Pharmaceuticals International, Plc | $65.97 | 2024 | Arcalyst |
| Medicomp INC | $58.12 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.73 | 2019 | |
| Medline Industries Lp | $35.72 | 2019-2021 | |
| Ethicon US, LLC | $33.65 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $30.73 | 2023 | Inpefa |
| Alnylam Pharmaceuticals INC. | $26.45 | 2024 | Onpattro |
| Kestra Medical Technology Services, INC. | $21.14 | 2023 | Assure Wcd |
| Akcea Therapeutics, INC. | $20.69 | 2020 | |
| Terumo Medical Corporation | $19.74 | 2021 | |
| Bardy Diagnostics, INC. | $15.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sameer Satija listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.